Research report | RaaS Watchlist: Waking the Sleeping Giant
RaaS Research Group has released a Watchlist report highlighting Avecho’s strong position as we progress our CBD insomnia treatment through Phase III trials.
Senior analyst Naheed Rahman notes:
“Avecho Biotechnology Limited (ASX:AVE) is an Australian biotech company focused on enhancing drug absorption through its proprietary TPM (Tocopheryl Phosphate Mixture). AVE is currently focusing its efforts on a CBD (cannabidiol) soft-gel capsule for treating insomnia. AVE is currently undergoing a pivotal Phase III clinical trial of the drug with the potential to be the first over-the-counter (OTC) CBD sleep aid approved by Australia’s Therapeutic Goods Administration (TGA).”
“In March 2025, AVE signed a licensing agreement with Sandoz, a global pharmaceutical company, for sales in Australia. This validates its lead product and de-risks commercialisation.”
“The company is arguably substantially undervalued currently, when considering its market cap of around A$20m for a biotech company already at the Phase III stage, and with the backing of a large multinational pharmaceutical company (Sandoz).”